Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Garp1on Dec 15, 2016 9:14am

86 Views

Post# 25603284

RE:RE:TH's Expanded Access Program highlighted in article

I agree also, but Thera did not announce or show any action on it (this is not new information). We don't know if or when Thera's sales force started to sell to their client the advantage of joining the expanded access program (I would imagine immediately after November 10th). One thing for sure, the more patients join the expanded access program the more we establish a guaranteed base of revenues.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?